Chronic Obstructive Pulmonary Disease Clinical Trial
— BEVAOfficial title:
Endoscopic Long Volume Reduction by Endobronchial Valves in Belgium
NCT number | NCT03264768 |
Other study ID # | s60207 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 1, 2017 |
Est. completion date | December 2020 |
This a single center non-randomised non-sham controlled intervention study evaluating the effectiveness and safety of endoscopic lung volume reduction by endobronchial valves
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 2020 |
Est. primary completion date | September 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Age 40 - 75 years - Confluent or destructive heterogeneous emphysema on CT - Smoking cessation for at least 6m (proven by urinary cotinine levels) - FEV1 < 60 %predicted, RV > 150 %predicted, TLC > 90 %predicted - RV/TLC ratio = 0.55 - 6MWD < 450 meter - mMRC = 2 - Visual estimation of 70% complete fissure between target lobe and adjacent lobe on CT of referring physician - LABA-LAMA bronchodilator therapy as a minimum therapy - Able to sign informed consent Exclusion Criteria: - Homogenous emphysema - PaCO2 > 60 mmHg with ambient air - PaO2 < 45 mmHg with ambient air - Previous LVRS, lung transplantation, lobectomy - TLCO or FEV1 < 20% predicted - Significant pulmonary hypertension (PaPsyst > 50 mm Hg) - Heart failure with reduced EF (< 40%) - 6MWD < 100 meter - BODE index = 7 and eligible for transplantation - Active cancer - Life expectancy < 3 months - Significant lung disease other than COPD/emphysema - Unable to comply with study procedures |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Leuven | Leuven | Flanders |
Lead Sponsor | Collaborator |
---|---|
KU Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in FEV1 (liters), FVC (liters), RV (liters), TLC (liters) at 3 and 6 months post intervention | Absolute difference from baseline values (liters) | 3 months and 6 months post intervention | |
Other | Change in RV/TLC ratio (%) at 3 and 6 months post intervention | Absolute difference from baseline values (%) | 3 months and 6 months post intervention | |
Other | Change in 6MWD (meters) at 3 and 6 months post intervention | Absolute difference from baseline values (meters) | 3 months and 6 months post intervention | |
Other | Change in physical activity at 3 months post intervention | Absolute difference in stepcounts per day (n) from baseline values | 3 months post intervention | |
Other | Change in ProActive clinical visit questionnaire | Absolute difference in points from baseline values | 3 months post intervention | |
Other | Change in BODE index | Absolute difference in points from baseline values | 3 months and 6 months post intervention | |
Other | changes in physical activity between 3 and 6 months of follow up (telecoaching period) | Absolute difference in stepcounts per day (n) 3 months - 6 months post allocation | 3 months - 6 months post allocation | |
Other | changes in ProActive clinical visit questionnaire between 3 and 6 months of follow up (telecoaching period) | Absolute difference in points 3 months - 6 months post allocation | 3 months - 6 months post allocation | |
Other | Comparing change in FEV1 (liters), FVC (liters), RV (liters), TLC (liters) at 3 and 6 months post EBV and LVRS | Absolute difference from baseline values (liters) for both interventions | 3 months and 6 months post intervention (endoscopic or surgical) | |
Other | Comparing change in 6MWD at 3 and 6 months post EBV and LVRS | Absolute difference from baseline values (meters) for both interventions | 3 months and 6 months post intervention (endoscopic or surgical) | |
Other | Comparing change in physical activity at 3 and 6 months post EBV and LVRS | Absolute difference from baseline values (amount of steps per day) for both interventions | 3 months and 6 months post intervention (endoscopic or surgical) | |
Other | Comparing change in SGRQ at 3 and 6 months post EBV and LVRS | Absolute difference from baseline values for both interventions | 3 months and 6 months post intervention (endoscopic or surgical) | |
Primary | response rate of FEV1 at 3 months post intervention | proportion of patients with a minimal change of FEV1 > 100 ml | 3 months | |
Secondary | response rate on SGRQ at 3 months and 6 months post intervention | proportion of patients with a minimal change of -4 points on SGRQ | 3 months and 6 months post intervention | |
Secondary | response rate on 6 minutes walking distance (6MWD) at 3 months and 6 months post intervention | proportion of patients with a minimal improvement of 30 meters on 6MWD | 3 months and 6 months post intervention | |
Secondary | response rate on residual volume (RV) at 3 months and 6 months post intervention | proportion of patients with a minimal reduction of 400 ml on residual volume | 3 months and 6 months post intervention | |
Secondary | response rate on FEV1 at 6 months post intervention | proportion of patients with a minimal change of FEV1 > 100 ml | 6 months | |
Secondary | response rate on Transitional dyspnee index (TDI) at 3 months and 6 months post intervention | proportion of patients with a minimal change of -1 point on TDI | 3 months and 6 months post intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|